Insider Selling: LeMaitre Vascular Inc (NASDAQ:LMAT) Director Sells $481,500.00 in Stock

LeMaitre Vascular Inc (NASDAQ:LMAT) Director Michael H. Thomas sold 15,000 shares of the company’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $32.10, for a total transaction of $481,500.00. Following the completion of the sale, the director now owns 15,000 shares in the company, valued at approximately $481,500. The sale was disclosed in a filing with the SEC, which is accessible through this link.

LMAT opened at $31.00 on Friday. The firm has a market cap of $631.93 million, a price-to-earnings ratio of 36.90, a price-to-earnings-growth ratio of 3.70 and a beta of 1.15. LeMaitre Vascular Inc has a fifty-two week low of $21.79 and a fifty-two week high of $38.99. The company’s 50-day moving average price is $30.43 and its 200 day moving average price is $28.61.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Wednesday, July 24th. The medical instruments supplier reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.02. The firm had revenue of $29.48 million for the quarter, compared to analyst estimates of $28.90 million. LeMaitre Vascular had a net margin of 16.72% and a return on equity of 13.15%. LeMaitre Vascular’s quarterly revenue was up 9.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 earnings per share. Equities analysts anticipate that LeMaitre Vascular Inc will post 0.86 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 5th. Investors of record on Wednesday, August 21st will be paid a dividend of $0.085 per share. The ex-dividend date of this dividend is Tuesday, August 20th. This represents a $0.34 annualized dividend and a yield of 1.10%. LeMaitre Vascular’s dividend payout ratio (DPR) is 40.48%.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC raised its stake in LeMaitre Vascular by 2.5% during the second quarter. Conestoga Capital Advisors LLC now owns 1,741,196 shares of the medical instruments supplier’s stock worth $48,719,000 after acquiring an additional 42,315 shares during the period. Vanguard Group Inc. grew its position in LeMaitre Vascular by 0.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,336,600 shares of the medical instruments supplier’s stock worth $37,398,000 after purchasing an additional 11,508 shares during the last quarter. Copeland Capital Management LLC grew its position in LeMaitre Vascular by 150.7% in the 2nd quarter. Copeland Capital Management LLC now owns 386,557 shares of the medical instruments supplier’s stock worth $10,816,000 after purchasing an additional 232,351 shares during the last quarter. Northern Trust Corp grew its position in LeMaitre Vascular by 0.5% in the 2nd quarter. Northern Trust Corp now owns 264,793 shares of the medical instruments supplier’s stock worth $7,408,000 after purchasing an additional 1,345 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in LeMaitre Vascular by 3.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 262,851 shares of the medical instruments supplier’s stock worth $7,355,000 after purchasing an additional 8,942 shares during the last quarter. Hedge funds and other institutional investors own 78.35% of the company’s stock.

Several research firms recently weighed in on LMAT. BidaskClub upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Friday, July 19th. Lake Street Capital increased their price objective on shares of LeMaitre Vascular from $27.00 to $34.00 and gave the stock a “hold” rating in a research note on Thursday, July 25th. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective on the stock in a research note on Saturday, July 27th. ValuEngine upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Monday, July 22nd. Finally, Barrington Research reiterated an “outperform” rating and set a $37.00 price objective (up previously from $32.00) on shares of LeMaitre Vascular in a research note on Thursday, July 25th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $35.33.

About LeMaitre Vascular

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

See Also: Economic Reports

Insider Buying and Selling by Quarter for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.